Ron Renaud is Cerevel’s President & Chief Executive Officer, and he serves as a member of our board of directors.
Prior to joining Cerevel, Mr. Renaud served as a partner at Bain Capital Life Sciences from September 2022 to June 2023. Previously, he led Translate Bio as chairman and chief executive officer from 2014 until the close of its acquisition by Sanofi in September 2021. During his tenure, he transformed the company from a start-up platform into a leading mRNA company, following the strategic acquisition of mRNA assets from Shire for $110 million in 2016. Building upon that investment, Mr. Renaud developed a strong corporate culture and a robust research and development organization, and ultimately generated significant returns for shareholders when Sanofi acquired the company for $3.2 billion.
Mr. Renaud was at Idenix Pharmaceuticals from 2007 through 2014, where he served as chief financial officer, chief business officer and finally, president and chief executive officer. At the start of his CEO tenure, the market capitalization of Idenix was $300 million, and through streamlining of operations, increasing employee engagement, and more focused research and development supported by significant capital raises, he led the company to an acquisition by Merck at a value of $3.85 billion.
Earlier in Mr. Renaud‘s career, he was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. Mr. Renaud also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance.
Mr. Renaud earned his bachelor’s degree from St. Anselm College and an MBA from the Marshall School of Business at the University of Southern California.
What is Ronald C. Renaud, Jr.'s net worth?
The estimated net worth of Ronald C. Renaud, Jr. is at least $3.77 million as of August 3rd, 2023. Mr. Renaud, Jr. owns 83,857 shares of Cerevel Therapeutics stock worth more than $3,770,211 as of December 18th. This net worth estimate does not reflect any other investments that Mr. Renaud, Jr. may own. Learn More about Ronald C. Renaud, Jr.'s net worth.
How do I contact Ronald C. Renaud, Jr.?
Has Ronald C. Renaud, Jr. been buying or selling shares of Cerevel Therapeutics?
Ronald C. Renaud, Jr. has not been actively trading shares of Cerevel Therapeutics during the past quarter. Most recently, on Thursday, August 3rd, Ronald C. Renaud, Jr. bought 83,857 shares of Cerevel Therapeutics stock. The stock was acquired at an average cost of $23.96 per share, with a total value of $2,009,213.72. Following the completion of the transaction, the chief executive officer now directly owns 83,857 shares of the company's stock, valued at $2,009,213.72. Learn More on Ronald C. Renaud, Jr.'s trading history.
Who are Cerevel Therapeutics' active insiders?
Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.
Are insiders buying or selling shares of Cerevel Therapeutics?
In the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 219,364 shares worth more than $9,091,856.92. The most recent insider tranaction occured on July, 1st when Director N Anthony Coles sold 25,000 shares worth more than $1,029,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company.
Learn More about insider trades at Cerevel Therapeutics. Information on this page was last updated on 7/1/2024.
